Contralateral breast cancer in patients with ductal carcinoma in situ and invasive breast cancer in the Netherlands
Background: The cumulative incidence of invasive contralateral breast cancer (CBC) for patients with first invasive breast cancer (BC) is approximately 0.4% per year. Less is known about CBC risk in patients with ductal carcinoma in situ (DCIS). We aimed to assess the CBC risk in patients with first DCIS compared to those with invasive BC, taking age, screening period, and (neo) adjuvant systemic therapy into account.
ConclusionThe presence of breast cancer does not significantly increase the likelihood for upgrade at a separate site of ipsilateral concurrent ADH above contemporary reported upgrade rates of ADH alone (10 –30%). When considering breast conservation for breast cancer, omitting excision of the site of ADH can be considered when low-risk features are present.
MONDAY, Oct. 5, 2020 -- Research following patients for nearly three decades finds that surgery plus radiation beats surgery alone for women with ductal carcinoma in situ (DCIS) -- a common, early form of breast cancer that can become invasive...
ConclusionDetermining the specific immune response in each subtype could be helpful in estimating the possible behavior of the tumor cells in TME. It is important to realize that different frequencies of immune cells in BC environment likely determine the patients ’ prognosis and their survival in each subtype. Therefore, elucidation of the distinct immune players in TME would be helpful toward developing targeted therapies in each subtype.
Risk for dying from breast cancer remains elevated 15 years after initial diagnosis
This study aimed to assess the long-term risk of ipsilateral subsequent in situ and invasive lesions after a diagnosis of primary DCIS and the association with initial DCIS treatment.
This study aims to be the first to explore if concomitant DCIS affects the clinical behavior in terms of disease progression and overall survival among Asian patients with IDC.
Background: Ductal carcinoma in situ (DCIS) identified by screening mammography accounts for 20% of breast cancer diagnoses, and microinvasion (DCIS-M) is found in 5% –10%. There are no defined treatment guidelines for palpable DCIS or DCIS-M. The role of screening mammography is now being questioned across the world and in the developing world with no national screening programs, women with DCIS present with a palpable lump in the breast. We conducted a retros pective audit of women with DCIS treated at our institution to classify palpable DCIS and DCIS-M as distinct clinical stages and emphasize the need for a chan...
Background: Breast cancer treatment guidelines recommend the surgeon perform a sentinel lymph node biopsy (SLNB) for patients with ductal carcinoma in situ (DCIS) who have a high risk of invasive cancer or for whom a mastectomy is planned.
ConclusionsMS of ultrafast DCE-MRI is useful for predicting the prognostic factors of breast cancer.Secondary abstractHigher maximum slope (MS) is significantly associated with an invasive breast cancer component. Higher MS is significantly associated with an axillary lymph node metastasis. MS becomes significantly higher with increasing ki-67 (a proliferation marker). Ultrafast MRI is useful for predicting the prognostic factors of breast cancer.
Background: Low-risk ductal carcinoma in situ (DCIS) lesions carry a risk of progressing to invasive breast cancer (iBC). Therefore, women with DCIS undergo surgery ±radiotherapy which will yield many of them no/limited survival benefit whilst the associated side-effects can significantly impact their quality of life (QoL). The safety of active surveillance (AS) via yearly mammographic screening for low-risk DCIS is now being investigated. AS minimizes the phy sical burden associated with the standard treatments, but foregoing treatment could cause increased worry about progression of the DCIS lesion to iBC.